SWOG Cancer Research Network
@swog.org
SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million+ years of life. Founded by the National Cancer Institute in 1956. Member NCTN & NCORP. Online at swog.org. @SupportingSWOG.bsky.social partner.
"Cancer statistics, 2026: Charting a course for a national cancer research agenda," commentary by Dr. Primo Lara, Jr, & @drdawnhershman.bsky.social publ w the annual portrait of U.S. #cancer stats in CA: A Cancer Journal for Clinicians, just out! #NCTN #NCORP @eaonc.bsky.social @nrgonc.bsky.social
Cancer statistics, 2026: Charting a course for a national cancer research agenda
Click on the article title to read more.
doi.org
January 13, 2026 at 10:21 PM
"Cancer statistics, 2026: Charting a course for a national cancer research agenda," commentary by Dr. Primo Lara, Jr, & @drdawnhershman.bsky.social publ w the annual portrait of U.S. #cancer stats in CA: A Cancer Journal for Clinicians, just out! #NCTN #NCORP @eaonc.bsky.social @nrgonc.bsky.social
S2213 is a randomized ph 3 to definitively learn role of transplant in pts newly diagnosed w AL #amyloidosis.
BMT-CTN Champion: Anita D'Souza, MD
SWOG.org/clinical-trials/S2213
BMT-CTN Champion: Anita D'Souza, MD
SWOG.org/clinical-trials/S2213
January 12, 2026 at 2:20 PM
S2213 is a randomized ph 3 to definitively learn role of transplant in pts newly diagnosed w AL #amyloidosis.
BMT-CTN Champion: Anita D'Souza, MD
SWOG.org/clinical-trials/S2213
BMT-CTN Champion: Anita D'Souza, MD
SWOG.org/clinical-trials/S2213
Treated for muscle invasive bladder cancer and want to keep your bladder? Ask your doctor about #ClinicalTrial S2427 (BRIGHT).
SWOG.org/S2427. 1-800-4-CANCER. #KeepMyBladder #MIBC
SWOG.org/S2427. 1-800-4-CANCER. #KeepMyBladder #MIBC
January 9, 2026 at 8:35 PM
Treated for muscle invasive bladder cancer and want to keep your bladder? Ask your doctor about #ClinicalTrial S2427 (BRIGHT).
SWOG.org/S2427. 1-800-4-CANCER. #KeepMyBladder #MIBC
SWOG.org/S2427. 1-800-4-CANCER. #KeepMyBladder #MIBC
Extensive stage small cell lung cancer can be hard to treat — but study S2409 (the PRISM trial) is looking for better, personalized options. To learn more, visit SWOG.org/S2409 or call 1-800-4-CANCER. #LCSM #SCLC
January 8, 2026 at 4:45 PM
Extensive stage small cell lung cancer can be hard to treat — but study S2409 (the PRISM trial) is looking for better, personalized options. To learn more, visit SWOG.org/S2409 or call 1-800-4-CANCER. #LCSM #SCLC
S2213 is an #ALamyloidosis #clinicaltrial to determine if Dara-VCD drug treatment or stem cell transplant is better for patients. The study may be an option for you if your treatment plan could safely include a stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4- CANCER.
January 6, 2026 at 8:15 PM
S2213 is an #ALamyloidosis #clinicaltrial to determine if Dara-VCD drug treatment or stem cell transplant is better for patients. The study may be an option for you if your treatment plan could safely include a stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4- CANCER.
Reposted by SWOG Cancer Research Network
For all #SWOGonc early career GU researchers:
The Nicholas Vogelzang GU Scholars Program
Includes mentorship and travel support - apply by January 15
w/ @swog.org
thehopefoundation.org/vogelzang-gu...
The Nicholas Vogelzang GU Scholars Program
Includes mentorship and travel support - apply by January 15
w/ @swog.org
thehopefoundation.org/vogelzang-gu...
January 3, 2026 at 2:59 PM
For all #SWOGonc early career GU researchers:
The Nicholas Vogelzang GU Scholars Program
Includes mentorship and travel support - apply by January 15
w/ @swog.org
thehopefoundation.org/vogelzang-gu...
The Nicholas Vogelzang GU Scholars Program
Includes mentorship and travel support - apply by January 15
w/ @swog.org
thehopefoundation.org/vogelzang-gu...
#ClinicalTrial S2409 (PRISM) asks if it’s possible to personalize treatment for extensive stage small cell lung cancer. It compares standard treatment alone to standard treatment plus a drug matched to the cancer subtype. Learn more: SWOG.org/S2409 or 1-800-4-CANCER.
January 2, 2026 at 9:45 PM
#ClinicalTrial S2409 (PRISM) asks if it’s possible to personalize treatment for extensive stage small cell lung cancer. It compares standard treatment alone to standard treatment plus a drug matched to the cancer subtype. Learn more: SWOG.org/S2409 or 1-800-4-CANCER.
Have you had treatment for muscle invasive #BladderCancer? Are you expecting surgery next?
If your scans show no cancer, you may be able to join #ClinicalTrial S2427 (also called BRIGHT).
Visit SWOG.org/S2427 to learn more. Or call 1-800-4-CANCER. #BladderPreservation
If your scans show no cancer, you may be able to join #ClinicalTrial S2427 (also called BRIGHT).
Visit SWOG.org/S2427 to learn more. Or call 1-800-4-CANCER. #BladderPreservation
January 1, 2026 at 6:10 PM
Have you had treatment for muscle invasive #BladderCancer? Are you expecting surgery next?
If your scans show no cancer, you may be able to join #ClinicalTrial S2427 (also called BRIGHT).
Visit SWOG.org/S2427 to learn more. Or call 1-800-4-CANCER. #BladderPreservation
If your scans show no cancer, you may be able to join #ClinicalTrial S2427 (also called BRIGHT).
Visit SWOG.org/S2427 to learn more. Or call 1-800-4-CANCER. #BladderPreservation
Reposted by SWOG Cancer Research Network
In a multi-trial analysis led by Fred Hutch's Dr. Joe Unger, patients reporting fatigue prior to systemic cancer treatment faced 2x the risk for severe toxic effects and nearly 5x the risk for fatal complications compared with those with minimal to no fatigue. @swog.org https://wb.md/3LozLE8
Fatigue Before Cancer Therapy Predicts Toxicity Risk
Patients' fatigue levels before starting systemic cancer treatment predict their risk for severe or fatal side effects.
wb.md
December 30, 2025 at 9:06 PM
In a multi-trial analysis led by Fred Hutch's Dr. Joe Unger, patients reporting fatigue prior to systemic cancer treatment faced 2x the risk for severe toxic effects and nearly 5x the risk for fatal complications compared with those with minimal to no fatigue. @swog.org https://wb.md/3LozLE8
Just activated!
#NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice SOC w/wo panitumumab. #pancsm
PI: Rachael A. Safyan, MD @fredhutch.org
swog.org/clinical-tri...
#NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice SOC w/wo panitumumab. #pancsm
PI: Rachael A. Safyan, MD @fredhutch.org
swog.org/clinical-tri...
December 30, 2025 at 3:53 PM
Just activated!
#NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice SOC w/wo panitumumab. #pancsm
PI: Rachael A. Safyan, MD @fredhutch.org
swog.org/clinical-tri...
#NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice SOC w/wo panitumumab. #pancsm
PI: Rachael A. Safyan, MD @fredhutch.org
swog.org/clinical-tri...
In @jamaoncology.com:
higher baseline fatigue assoc w higher risk of severe #cancer treatment-related toxic effects. Initial fatigue assessment may be early marker of risk for SAEs & inform personalized therapy. @drjoeunger.bsky.social @drdawnhershman.bsky.social @fischmd.bsky.social @fredhutch.org
higher baseline fatigue assoc w higher risk of severe #cancer treatment-related toxic effects. Initial fatigue assessment may be early marker of risk for SAEs & inform personalized therapy. @drjoeunger.bsky.social @drdawnhershman.bsky.social @fischmd.bsky.social @fredhutch.org
Among over 7000 patients with #cancer, higher baseline fatigue before systemic therapy was linked to an increased risk of severe, life-threatening, and fatal adverse events. ja.ma/4qmZtrt
December 29, 2025 at 6:32 PM
In @jamaoncology.com:
higher baseline fatigue assoc w higher risk of severe #cancer treatment-related toxic effects. Initial fatigue assessment may be early marker of risk for SAEs & inform personalized therapy. @drjoeunger.bsky.social @drdawnhershman.bsky.social @fischmd.bsky.social @fredhutch.org
higher baseline fatigue assoc w higher risk of severe #cancer treatment-related toxic effects. Initial fatigue assessment may be early marker of risk for SAEs & inform personalized therapy. @drjoeunger.bsky.social @drdawnhershman.bsky.social @fischmd.bsky.social @fredhutch.org
S2213 is a randomized ph 3 to definitively learn the role of transplant in pts newly diagnosed w AL #amyloidosis.
ECOG-ACRIN Cancer Research Group Champion: Taxiarchis Kourelis, MD
SWOG.org/clinical-trials/S2213
ECOG-ACRIN Cancer Research Group Champion: Taxiarchis Kourelis, MD
SWOG.org/clinical-trials/S2213
December 29, 2025 at 2:10 PM
S2213 is a randomized ph 3 to definitively learn the role of transplant in pts newly diagnosed w AL #amyloidosis.
ECOG-ACRIN Cancer Research Group Champion: Taxiarchis Kourelis, MD
SWOG.org/clinical-trials/S2213
ECOG-ACRIN Cancer Research Group Champion: Taxiarchis Kourelis, MD
SWOG.org/clinical-trials/S2213
Bladder removal surgery can have a big impact on quality of life. Study S2427 (also called BRIGHT) is testing a possible #BladderSparing approach for people with muscle invasive #BladderCancer. To learn more, visit SWOG.org/S2427 or call 1-800-4-CANCER. #MIBC
December 24, 2025 at 4:20 PM
Bladder removal surgery can have a big impact on quality of life. Study S2427 (also called BRIGHT) is testing a possible #BladderSparing approach for people with muscle invasive #BladderCancer. To learn more, visit SWOG.org/S2427 or call 1-800-4-CANCER. #MIBC
Reposted by SWOG Cancer Research Network
Our program offerings kick off right away in 2026.
#SWOGonc members, please don't miss our January 15 deadline for CRA and nurse travel to the spring @swog.org group meeting!
thehopefoundation.org/funding-oppo...
#SWOGonc members, please don't miss our January 15 deadline for CRA and nurse travel to the spring @swog.org group meeting!
thehopefoundation.org/funding-oppo...
December 19, 2025 at 8:03 PM
Our program offerings kick off right away in 2026.
#SWOGonc members, please don't miss our January 15 deadline for CRA and nurse travel to the spring @swog.org group meeting!
thehopefoundation.org/funding-oppo...
#SWOGonc members, please don't miss our January 15 deadline for CRA and nurse travel to the spring @swog.org group meeting!
thehopefoundation.org/funding-oppo...
If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t started initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC
December 23, 2025 at 5:05 PM
If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t started initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC
Study S2213 asks if a drug combination known as Dara-VCD or stem cell transplant is better for treating AL #amyloidosis. It tests how well the treatments work, and how they affect quality of life. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease #clinicaltrial
December 22, 2025 at 8:05 PM
Study S2213 asks if a drug combination known as Dara-VCD or stem cell transplant is better for treating AL #amyloidosis. It tests how well the treatments work, and how they affect quality of life. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease #clinicaltrial
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials
doi.org/10.1158/1078...
FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials
doi.org/10.1158/1078...
December 19, 2025 at 4:26 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials
doi.org/10.1158/1078...
FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials
doi.org/10.1158/1078...
#ClinicalTrial S2409 PRISM randomizes patients with extensive stage small cell lung cancer to durvalumab with or without a drug that’s targeted to their specific #SCLC subtype.
Co-PI: Nan Sethakorn, MD, PhD - Loyola Univ Medical Center
swog.org/clinical-trials/S2409
Co-PI: Nan Sethakorn, MD, PhD - Loyola Univ Medical Center
swog.org/clinical-trials/S2409
December 19, 2025 at 3:30 PM
#ClinicalTrial S2409 PRISM randomizes patients with extensive stage small cell lung cancer to durvalumab with or without a drug that’s targeted to their specific #SCLC subtype.
Co-PI: Nan Sethakorn, MD, PhD - Loyola Univ Medical Center
swog.org/clinical-trials/S2409
Co-PI: Nan Sethakorn, MD, PhD - Loyola Univ Medical Center
swog.org/clinical-trials/S2409
S2427 BRIGHT trial tests IO + RT as bladder-preserving tx for patients with MIBC who respond to NAT.
PROs track QoL and treatment-related symptomatic toxicities.
Systematic biopsies needed at post-NAT TURBT.
Co-PI: James B. Yu, MD, MHS, Dartmouth Cancer Center
swog.org/clinical-trials/S2427
PROs track QoL and treatment-related symptomatic toxicities.
Systematic biopsies needed at post-NAT TURBT.
Co-PI: James B. Yu, MD, MHS, Dartmouth Cancer Center
swog.org/clinical-trials/S2427
December 18, 2025 at 3:55 PM
S2427 BRIGHT trial tests IO + RT as bladder-preserving tx for patients with MIBC who respond to NAT.
PROs track QoL and treatment-related symptomatic toxicities.
Systematic biopsies needed at post-NAT TURBT.
Co-PI: James B. Yu, MD, MHS, Dartmouth Cancer Center
swog.org/clinical-trials/S2427
PROs track QoL and treatment-related symptomatic toxicities.
Systematic biopsies needed at post-NAT TURBT.
Co-PI: James B. Yu, MD, MHS, Dartmouth Cancer Center
swog.org/clinical-trials/S2427
If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t finished initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC
December 17, 2025 at 8:10 PM
If you have extensive stage small cell lung cancer (ES-SCLC) and you haven’t finished initial treatment, ask your doctor about study S2409 (PRISM). It tests the cancer for certain features to match patients with treatments. SWOG.org/S2409. 1-800-4-CANCER. #LCSM #SCLC
Are you getting treatment for muscle invasive bladder cancer? Ask your doctor about S2427 (BRIGHT). It’s a #ClinicalTrial testing whether an immunotherapy drug plus radiation therapy can help patients keep their bladder. SWOG.org/S2427. 1-800-4-CANCER. #MIBC
December 16, 2025 at 9:05 PM
Are you getting treatment for muscle invasive bladder cancer? Ask your doctor about S2427 (BRIGHT). It’s a #ClinicalTrial testing whether an immunotherapy drug plus radiation therapy can help patients keep their bladder. SWOG.org/S2427. 1-800-4-CANCER. #MIBC
What’s the best consolidation tx for patients newly diagnosed with #ALamyloidosis: #StemCellTransplant w melphalan? Or daratumumab + VCD? Trial S2213 also compares minimal residual disease negativity rates.
TM Co-PI: Brian Walker, PhD - Indiana Univ School of Medicine
SWOG.org/clinical-trials/S2213
TM Co-PI: Brian Walker, PhD - Indiana Univ School of Medicine
SWOG.org/clinical-trials/S2213
December 15, 2025 at 8:00 PM
What’s the best consolidation tx for patients newly diagnosed with #ALamyloidosis: #StemCellTransplant w melphalan? Or daratumumab + VCD? Trial S2213 also compares minimal residual disease negativity rates.
TM Co-PI: Brian Walker, PhD - Indiana Univ School of Medicine
SWOG.org/clinical-trials/S2213
TM Co-PI: Brian Walker, PhD - Indiana Univ School of Medicine
SWOG.org/clinical-trials/S2213
Reposted by SWOG Cancer Research Network
Awesome 👏🏾 Barbara 👏🏾 Honored to be included in Barbara Segarra’s plenary session @sabcs.bsky.social and proud to work alongside you! @swog.org @oncoalert.bsky.social @oncodaily.bsky.social #bcsm #breastcancer #advocates #oncoalert #clinicaltrials #research #SABCS25
December 11, 2025 at 5:07 PM
Awesome 👏🏾 Barbara 👏🏾 Honored to be included in Barbara Segarra’s plenary session @sabcs.bsky.social and proud to work alongside you! @swog.org @oncoalert.bsky.social @oncodaily.bsky.social #bcsm #breastcancer #advocates #oncoalert #clinicaltrials #research #SABCS25
Are you starting treatment for #ALAmyloidosis? Ask your doctor about #clinicaltrial S2213. It compares using a drug combination called Dara-VCD vs. stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease
December 12, 2025 at 1:55 PM
Are you starting treatment for #ALAmyloidosis? Ask your doctor about #clinicaltrial S2213. It compares using a drug combination called Dara-VCD vs. stem cell transplant. Learn more at SWOG.org/S2213. Or call 1-800-4-CANCER. #raredisease
The S2409 PRISM trial biomarker-tests patients with extensive stage small cell #LungCancer during induction treatment and assigns them to 1 of 3 maintenance therapy cohorts based on #SCLC subtype and SLFN11 status. #LCSM
Co-PI: So Yeon Kim, MD Yale Cancer Center
swog.org/clinical-trials/S2409
Co-PI: So Yeon Kim, MD Yale Cancer Center
swog.org/clinical-trials/S2409
December 11, 2025 at 1:40 PM
The S2409 PRISM trial biomarker-tests patients with extensive stage small cell #LungCancer during induction treatment and assigns them to 1 of 3 maintenance therapy cohorts based on #SCLC subtype and SLFN11 status. #LCSM
Co-PI: So Yeon Kim, MD Yale Cancer Center
swog.org/clinical-trials/S2409
Co-PI: So Yeon Kim, MD Yale Cancer Center
swog.org/clinical-trials/S2409